News | August 05, 2024
Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Strong topline growth driven by solid performance across key brands.
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
GSK and Flagship to jointly fund up to $150 million upfront
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
